Table 9

Groups	Parameters	Total lipids (g/L)	Triglycerides (mg/dl)	Total cholesterol (mg/dl)	LDL- cholesterol (mg/dl)	HDL- cholesterol (mg/dl)	vLDL- cholesterol (mg/dl)	LDL/ HDL	Total chol./ HDL	HMGCo-A/ mevalonate
Normal		3.46±0.18^b	37.48±1.31^b	68.61±3.55^b	27.84±0.28^b	33.27±1.57^a	7.49±0.26^b	0.88±0.05^b	2.07±0.09^b	1.36±0.04^b
Diabetic control		4.82±0.34^a	46.35±2.14^a	80.12±1.77^a	42.83±1.76^a	28.14±1.24^a	9.27±0.43^a	1.54±0.11^a	2.87±0.18^a	1.59±0.02^a
Diabetic treated with 4b		3.47±0.07^b	36.50±081^b	76.13±2.47^ab	42.62±1.83^a	27.67±2.65^a	7.30±0.16^b	1.58±0.09^a	2.85±0.21^a	1.60±0.03^a
F-probability		P<0.01	P<0.001	P<0.05	P<0.001	P>0.05	P<0.001	P<0.001	P<0.01	P<0.001
LSD at 5% level		0.68	4.59	8.13	4.45	-	0.92	0.256	0.511	0.103
LSD at 1% level		0.94	6.35	11.24	6.16	-	1.27	0.355	0.706	0.144

Table 9: Effect of pyrimido[1,6-a]quinazoline derivative 4b on serum lipid profile in n5-STZ induced type 2 diabetic female rats.